Table 3.
Outcomes by mutation status of specific genes occurring in at least 3 patients
| Gene | n (%) | Mutated | Wild-type | P |
|---|---|---|---|---|
| CR rate, % | ||||
| DNA methylation pathway* | 15 (37) | 60 | 22 | .027 |
| SRSF2 | 11 (27) | 22 | 46 | .204 |
| RUNX1 | 7 (17) | 17 | 44 | .217 |
| NPM1 | 6 (15) | 83 | 30 | .025 |
| TP53 | 5 (12) | 0 | 46 | .065 |
| BCOR | 4 (10) | 75 | 35 | .157 |
| FLT3 | 4 (10) | 67 | 37 | .338 |
| STAG2 | 4 (10) | 0 | 45 | .118 |
| CEPBA | 3 (7) | 100 | 33 | .052 |
| RAD21 | 3 (7) | 100 | 33 | .052 |
| NF1 | 3 (7) | 0 | 41 | .606 |
| Median OS, mo | ||||
| SRSF2 | 11 (27) | 10.7 | 19.1 | .23 |
| DNMT3A | 8 (20) | 13.5 | 19.1 | .874 |
| IDH2 | 7 (17) | Not reached | 14.9 | .209 |
| RUNX1 | 7 (17) | 8 | 18.2 | .078 |
| NPM1 | 6 (15) | Not reached | 14.9 | .133 |
| TET2 | 5 (12) | 20.1 | 17.8 | .786 |
| TP53 | 5 (12) | 7.6 | 19.1 | .668 |
| BCOR | 4 (10) | 19.1 | 17.8 | .382 |
| FLT3 | 4 (10) | 7.6 | 18.2 | .939 |
| STAG2 | 4 (10) | 8 | 19.1 | .768 |
| CEBPA | 3 (7) | Not reached | 14.9 | .061 |
| RAD21 | 3 (7) | 22.9 | 14.9 | .626 |
| NF1 | 3 (7) | 3 | 19.1 | .005 |
*
DNMT3A, IDH1, IDH2, or TET2.